Over-expression of MDR1 in amrubicinol-resistant lung cancer cells

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 3, 2011, Pages 669-676

  Takakuwa, Osamu ^a   Oguri, Tetsuya ^a   Ozasa, Hiroaki ^a   Uemura, Takehiro ^a   Kasai, Daishi ^a   Miyazaki, Mikinori ^a   Maeno, Ken ^a   Sato, Shigeki ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Amrubicin; Amrubicinol; Drug resistance; Lung cancer; MDR1; P glycoprotein

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; AMRUBICINOL; ANTHRACYCLINE ANTIBIOTIC AGENT; CISPLATIN; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GLYCOPROTEIN P; PACLITAXEL; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IC 50; LUNG CANCER; MDR1 GENE; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STRAIN DIFFERENCE;

ANIMALS; ANTHRACYCLINES; CALCIUM CHANNEL BLOCKERS; DRUG RESISTANCE, NEOPLASM; LLC-PK1 CELLS; LUNG NEOPLASMS; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, NEOPLASM; RNA, SMALL INTERFERING; SWINE; VERAPAMIL;

EID: 80054692266     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1533-4     Document Type: Article

References (33)

1. S Morisada Y Yanagi T Noguchi Y Kashiwazaki M Fukui 1989 Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts Jpn J Cancer Res 80 69 76 2496061 1:CAS:528:DyaL1MXhs1Glur8%3D
2. N Bernardini F Giannessi F Bianchi A Dolfi M Lupetti L Zaccaro G Malvaldi M Del Tacca 1991 Comparative activity of doxorubicin and its major metabolite, doxorubicinol, on V79/AP4 fibroblasts: a morphofunctional study Exp Mol Pathol 55 238 250 1748213 10.1016/0014-4800(91)90004-H 1:CAS:528:DyaK38XltFSlsQ%3D%3D
3. MJ Kuffel JM Reid MM Ames 1992 Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture Cancer Chemother Pharmacol 30 51 57 1586980 10.1007/BF00686485 1:CAS:528:DyaK38XkvVejtr0%3D
4. T Yamaoka M Hanada S Ichii S Morisada T Noguchi Y Yanagi 1998 Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells Jpn J Cancer Res 89 1067 1073 9849587 1:CAS:528:DyaK1cXnt1Oju7s%3D
5. T Yamaoka M Hanada S Ichii S Morisada T Noguchi Y Yanagi 1999 Uptake and intracellular distribution of amrubicin, a novel 9-amino-anthracycline, and its active metabolite amrubicinol in P388 murine leukemia cells Jpn J Cancer Res 90 685 690 10429662 1:CAS:528:DyaK1MXktFOhtbY%3D
6. T Yana S Negoro M Takada S Yokota Y Takada T Sugiura H Yamamoto T Sawa M Kawahara N Katakami Y Ariyoshi M Fukuoka West Japan Thoracic Oncology Group 2007 Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study Invest New Drugs 25 253 258 17039404 10.1007/s10637-006-9012-9 1:CAS:528:DC%2BD2sXltlartr0%3D
7. T Kurata I Okamoto K Tamura M Fukuoka 2007 Amrubicin for non-small-cell lung cancer and small-cell lung cancer Invest New Drugs 25 499 504 17628745 10.1007/s10637-007-9069-0 1:CAS:528:DC%2BD2sXos1Cit7w%3D
8. A Inoue S Sugawara K Yamazaki M Maemondo T Suzuki K Gomi S Takanashi C Inoue M Inage H Yokouchi H Watanabe T Tsukamoto Y Saijo O Ishimoto F Hommura T Nukiwa 2008 Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402 J Clin Oncol 26 5401 5406 18854562 10.1200/JCO.2008.18. 1974 1:CAS:528:DC%2BD1MXhslCmuw%3D%3D
9. DS Ettinger R Jotte P Lorigan V Gupta L Garbo C Alemany P Conkling DR Spigel AZ Dudek C Shah R Salgia R McNally MF Renschler JW Oliver 2010 Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer J Clin Oncol 28 2598 2603 20385980 10.1200/JCO.2009.26. 7682
10. K Kaira N Sunaga Y Tomizawa N Yanagitani K Shimizu H Imai M Utsugi Y Iwasaki H Iijima H Tsurumaki A Yoshii N Fueki T Hisada T Ishizuka R Saito M Mori 2010 A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer Lung Cancer 69 99 104 19853960 10.1016/j.lungcan.2009.09.012
11. A Hira H Watanabe Y Maeda K Yokoo E Sanematsu J Fujii J Sasaki A Hamada H Saito 2008 Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells Biochem Pharmacol 75 973 980 18054347 10.1016/j.bcp.2007. 10.023 1:CAS:528:DC%2BD1cXhsFymurg%3D
12. H Ozasa T Oguri T Uemura M Miyazaki K Maeno S Sato R Ueda 2010 Significance of thymidylate synthase for resistance to pemetrexed in lung cancer Cancer Sci 101 161 166 19811498 10.1111/j.1349-7006.2009.01358.x 1:CAS:528:DC%2BC3cXnvVOjtw%3D%3D
13. Y Bessho T Oguri H Ozasa T Uemura H Sakamoto M Miyazaki K Maeno S Sato R Ueda 2009 ABCC10/MRP7 is associated with vinorelbine resistance in non-small cell lung cancer Oncol Rep 21 263 268 19082471 1:CAS:528:DC%2BD1MXht1Cqtb4%3D
14. S Hoffmeyer O Burk O von Richter HP Arnold J Brockmöller A Johne I Cascorbi T Gerloff I Roots M Eichelbaum U Brinkmann 2000 Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci USA 28 3473 3478 10.1073/pnas.050585397
15. C Kimchi-Sarfaty JM Oh IW Kim ZE Sauna AM Calcagno SV Ambudkar MM Gottesman 2007 A "silent" polymorphism in the MDR1 gene changes substrate specificity Science 26 525 528 10.1126/science.1135308
16. ZE Sauna C Kimchi-Sarfaty SV Ambudkar MM Gottesman 2007 Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer Cancer Res 67 9609 9612 17942888 10.1158/0008-5472.CAN-07-2377 1:CAS:528:DC%2BD2sXhtFOnsLnO
17. MM Gottesman T Fojo SE Bates 2002 Multidrug resistance in cancer: role of ATP-dependent transporters Nat Rev Cancer 2 48 58 11902585 10.1038/nrc706 1:CAS:528:DC%2BD38XhvF2jtL8%3D
18. GD Leonard T Fojo SE Bates 2003 The role of ABC transporters in clinical practice Oncologist 8 411 424 14530494 10.1634/theoncologist.8-5-411 1:CAS:528:DC%2BD3sXoslyls74%3D
19. T Noguchi S Ichii S Morisada T Yamaoka Y Yanagi 1998 In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite Jpn J Cancer Res 89 1055 1060 9849585 1:CAS:528:DyaK1cXnt1Oju70%3D
20. H Wirth B Wermuth 1992 Immunohistochemical localization of carbonyl reductase in human tissues J Histochem Cytochem 40 1857 1863 1453004 10.1177/40.12.1453004 1:CAS:528:DyaK3sXnslKhtQ%3D%3D
21. Y Matsunaga A Hamada I Okamoto J Sasaki E Moriyama H Kishi M Matsumoto A Hira H Watanabe H Saito 2006 Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients Ther Drug Monit 28 76 82 16418698 10.1097/01.ftd.0000185771.82620.ee 1:CAS:528:DC%2BD28XkvFKmtQ%3D%3D
22. DD Ross LA Doyle W Yang Y Tong B Cornblatt 1995 Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance Biochem Pharmacol 50 1673 1683 7503771 10.1016/0006-2952(95)02069-1 1:CAS:528:DyaK2MXpvVWlt74%3D
23. Y Horio H Osada J Shimizu S Ogawa T Hida Y Sekido 2010 Relationship of mRNA expression of RanBP2 and topoisomerase II isoforms to cytotoxicity of amrubicin in human lung cancer cell lines Cancer Chemother Pharmacol 66 237 243 19809814 10.1007/s00280-009-1151-1 1:CAS:528:DC%2BC3cXmt1als78%3D
24. SL Lai LJ Goldstein MM Gottesman I Pastan CM Tsai BE Johnson JL Mulshine DC Ihde K Kayser AF Gazdar 1989 MDR1 gene expression in lung cancer J Natl Cancer Inst 81 1144 1150 2746668 10.1093/jnci/81.15.1144 1:STN:280: DyaL1MzhtFCqtw%3D%3D
25. BG Campling LC Young KA Baer YM Lam RG Deeley SP Cole JH Gerlach 1997 Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer Clin Cancer Res 3 115 122 9815546 1:CAS:528:DyaK2sXntlerug%3D%3D
26. LC Young BG Campling T Voskoglou-Nomikos SP Cole RG Deeley JH Gerlach 1999 Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response Clin Cancer Res 5 673 680 10100721 1:CAS:528:DyaK1MXitVyisbY%3D
27. N Triller P Korosec I Kern M Kosnik A Debeljak 2006 Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease Lung Cancer 54 235 240 16934363 10.1016/j.lungcan.2006.06.019
28. E Mechetner A Kyshtoobayeva S Zonis H Kim R Stroup R Garcia RJ Parker JP Fruehauf 1998 Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin Clin Cancer Res 4 389 398 9516927 1:CAS:528:DyaK1cXhtlSmsbs%3D
29. Y Tada M Wada T Migita J Nagayama E Hinoshita Y Mochida Y Maehara M Tsuneyoshi M Kuwano S Naito 2002 Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin Int J Cancer 98 630 635 11920626 10.1002/ijc.10246 1:CAS:528:DC%2BD38XitlSru7Y%3D
30. JH Pan JX Han JM Wu HN Huang QZ Yu LJ Sheng 2009 MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer Respiration 78 49 55 18812689 10.1159/000158454 1:CAS:528:DC%2BD1MXot12msLc%3D
31. JW Sohn SY Lee SJ Lee EJ Kim SI Cha CH Kim JT Lee TH Jung JY Park 2006 MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer Jpn J Clin Oncol 36 137 141 16478794 10.1093/jjco/hyi231
32. C Marzolini E Paus T Buclin RB Kim 2004 Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance Clin Pharmacol Ther 75 13 33 14749689 10.1016/j.clpt.2003.09.012 1:CAS:528:DC%2BD2cXntVKiuw%3D%3D
33. A Hamada J Sasaki S Saeki N Iwamoto M Inabe S Ushijima M Urata H Kishi S Fujii H Semba H Saito 2009 Association of pharmacokinetics and germ-line mutations in EGFR and ABC transporters with erlotinib toxicity in patients with non-small cell lung cancer (NSCLC) J Clin Oncol 27 109s (suppl; abstr 2506)